Alkermes (STU:8AK) Net Income From Continuing Operations : €401 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Alkermes Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Alkermes's net income from continuing operations for the three months ended in Mar. 2024 was €34 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €401 Mil.

Alkermes Net Income From Continuing Operations Historical Data

The historical data trend for Alkermes's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Net Income From Continuing Operations Chart

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-176.96

-91.13

-42.63

-149.40

326.23

Alkermes Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-39.08	218.81	44.75	103.42	33.88

Alkermes Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €401 Mil.

Alkermes (STU:8AK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (STU:8AK) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ALKS:USA 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Alkermes (STU:8AK) Headlines

No Headlines